Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LYRA Lyra Therapeutics	$7.33 -0.1%	$8.61	$3.81 ▼ $37.50	$12.02M	0.16	285,375 shs	2,830 shs
NEPH Nephros	$4.18 +4.0%	$3.80	$1.36 ▼ $5.00	$44.31M	1.11	27,499 shs	56,545 shs
WOK WORK Medical Technology Group	$0.78 +0.3%	$0.77	$0.36 ▼ $8.45	$43.82M	N/A	1.33 million shs	53,070 shs
ZYXI Zynex	$1.66 +8.5%	$2.14	$1.23 ▼ $9.42	$50.30M	0.91	260,180 shs	162,872 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LYRA Lyra Therapeutics	+1.24%	+3.38%	-10.49%	+59.91%	-56.17%
NEPH Nephros	-1.47%	+0.50%	+14.53%	+37.67%	+117.30%
WOK WORK Medical Technology Group	-3.36%	-1.58%	-0.91%	+10.44%	+77,309,900.00%
ZYXI Zynex	-0.65%	-3.77%	-37.30%	-35.98%	-80.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LYRA Lyra Therapeutics	3.1706 of 5 stars	3.0	5.0	0.0	0.0	2.7	2.5	0.6
NEPH Nephros	1.5084 of 5 stars	3.5	3.0	0.0	0.0	0.0	0.8	0.0
WOK WORK Medical Technology Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	2.4986 of 5 stars	3.2	1.0	0.0	0.0	1.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LYRA Lyra Therapeutics	2.00	Hold	$100.00	1,264.07% Upside
NEPH Nephros	3.00	Buy	$5.50	31.58% Upside
WOK WORK Medical Technology Group	0.00	N/A	N/A	N/A
ZYXI Zynex	2.33	Hold	$4.90	195.18% Upside

Current Analyst Ratings Breakdown

Latest LYRA, ZYXI, NEPH, and WOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	LYRA Lyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
8/8/2025	NEPH Nephros	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.50 ➝ $6.00
8/1/2025	ZYXI Zynex	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.70
8/1/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/15/2025	ZYXI Zynex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $3.00
6/30/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LYRA Lyra Therapeutics	$1.53M	7.86	N/A	N/A	$0.99 per share	7.41
NEPH Nephros	$14.16M	3.13	$0.02 per share	203.89	$0.91 per share	4.59
WOK WORK Medical Technology Group	$11.51M	3.81	N/A	N/A	$1.10 per share	0.70
ZYXI Zynex	$192.35M	0.26	$0.26 per share	6.31	$0.04 per share	41.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LYRA Lyra Therapeutics	-$93.43M	-$29.01	N/A	N/A	N/A	-5,043.64%	-404.56%	-60.06%	N/A
NEPH Nephros	$70K	$0.12	34.83	∞	N/A	7.95%	14.89%	11.64%	11/6/2025 (Estimated)
WOK WORK Medical Technology Group	-$3.49M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	$2.99M	-$0.94	N/A	3.53	N/A	-19.79%	-78.54%	-16.70%	10/30/2025 (Estimated)

Latest LYRA, ZYXI, NEPH, and WOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	LYRA Lyra Therapeutics	-$5.79	-$5.51	+$0.28	-$5.51	$0.18 million	$0.29 million
8/7/2025	Q2 2025	NEPH Nephros	-$0.0250	$0.02	+$0.0450	$0.02	$3.60 million	$4.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LYRA Lyra Therapeutics	N/A	N/A	N/A	N/A	N/A
NEPH Nephros	N/A	N/A	N/A	N/A	N/A
WOK WORK Medical Technology Group	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LYRA Lyra Therapeutics	N/A	2.78	2.78
NEPH Nephros	N/A	5.41	4.14
WOK WORK Medical Technology Group	N/A	N/A	N/A
ZYXI Zynex	0.56	0.62	0.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LYRA Lyra Therapeutics	95.62%
NEPH Nephros	41.10%
WOK WORK Medical Technology Group	N/A
ZYXI Zynex	29.68%

Insider Ownership

Company	Insider Ownership
LYRA Lyra Therapeutics	3.25%
NEPH Nephros	6.70%
WOK WORK Medical Technology Group	N/A
ZYXI Zynex	49.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LYRA Lyra Therapeutics	50	1.64 million	1.59 million	Optionable
NEPH Nephros	30	10.60 million	9.89 million	Not Optionable
WOK WORK Medical Technology Group	226	56.53 million	N/A	N/A
ZYXI Zynex	770	30.30 million	15.37 million	Optionable

LYRA, ZYXI, NEPH, and WOK Headlines

Recent News About These Companies

Contrasting Zynex (NASDAQ:ZYXI) & United Health Products (OTCMKTS:UEEC)

August 20 at 2:55 AM | americanbankingnews.com

Zynex announces new executive team

August 18, 2025 | msn.com

Zynex welcomes Steve Dyson as CEO, adds to leadership team

August 18, 2025 | proactiveinvestors.com

Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles

August 18, 2025 | prnewswire.com

Zynex, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14, 2025 | globenewswire.com

ZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

August 13, 2025 | globenewswire.com

Zynex Q2 Revenue Drops 55%

August 5, 2025 | fool.com

Zynex Inc. Faces Challenges Amid Strategic Shifts

August 4, 2025 | theglobeandmail.com

Zynex (NASDAQ:ZYXI) Raised to "Buy" at LADENBURG THALM/SH SH

August 2, 2025 | marketbeat.com

Zynex (NASDAQ:ZYXI) Rating Lowered to "Neutral" at HC Wainwright

August 2, 2025 | marketbeat.com

Zynex, Inc. (NASDAQ:ZYXI) Q2 2025 Earnings Call Transcript

August 1, 2025 | msn.com

HC Wainwright & Co. Downgrades Zynex (ZYXI)

August 1, 2025 | msn.com

Zynex, Inc.: Zynex Reports Second Quarter 2025 Financial Results

August 1, 2025 | finanznachrichten.de

Zynex Inc (ZYXI) Q2 2025 Earnings Report Preview: What to Look For

August 1, 2025 | finance.yahoo.com

Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript

July 31, 2025 | seekingalpha.com

Zynex Inc. (ZYXI) Reports Q2 Loss, Misses Revenue Estimates

July 31, 2025 | zacks.com

Zynex eyes growth revival under new CEO, advances oximeter technology

July 31, 2025 | proactiveinvestors.com

Zynex Reports Second Quarter 2025 Financial Results

July 31, 2025 | prnewswire.com

Zynex Sets Second Quarter 2025 Earnings Call

July 22, 2025 | prnewswire.com

Zynex: New CEO Steven Dyson shares his vision â€“ ICYMI

July 12, 2025 | proactiveinvestors.com

Zynex: New CEO Steven Dyson shares his vision – ICYMI

July 12, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA, ZYXI, NEPH, and WOK Company Descriptions

Lyra Therapeutics NASDAQ:LYRA

$7.33 -0.01 (-0.12%)

Closing price 03:57 PM Eastern

Extended Trading

$7.18 -0.15 (-2.06%)

As of 05:59 PM Eastern

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Nephros NASDAQ:NEPH

$4.18 +0.16 (+3.98%)

Closing price 04:00 PM Eastern

Extended Trading

$4.18 0.00 (0.00%)

As of 04:10 PM Eastern

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

WORK Medical Technology Group NASDAQ:WOK

$0.78 +0.00 (+0.27%)

Closing price 03:51 PM Eastern

Extended Trading

$0.78 +0.00 (+0.36%)

As of 04:52 PM Eastern

WORK Medical Technology Group Ltd. engages in developing health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

Zynex NASDAQ:ZYXI

$1.66 +0.13 (+8.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.65 -0.01 (-0.54%)

As of 07:00 PM Eastern

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time